PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 1 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $0 | – | 0 | – | 0.00% | – |
Q1 2021 | $0 | – | 0 | – | 0.00% | – |
Q4 2020 | $0 | – | 0 | – | 0.00% | – |
Q3 2020 | $0 | – | 0 | – | 0.00% | – |
Q2 2020 | $0 | – | 0 | – | 0.00% | – |
Q1 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q4 2019 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | – |
Q3 2019 | $2,000 | +100.0% | 300 | -12.0% | 0.00% | – |
Q4 2018 | $1,000 | -50.0% | 341 | 0.0% | 0.00% | – |
Q3 2018 | $2,000 | -33.3% | 341 | 0.0% | 0.00% | – |
Q2 2018 | $3,000 | +50.0% | 341 | 0.0% | 0.00% | – |
Q1 2018 | $2,000 | 0.0% | 341 | 0.0% | 0.00% | – |
Q4 2017 | $2,000 | -33.3% | 341 | -24.4% | 0.00% | – |
Q3 2017 | $3,000 | 0.0% | 451 | 0.0% | 0.00% | – |
Q2 2017 | $3,000 | -25.0% | 451 | 0.0% | 0.00% | – |
Q1 2017 | $4,000 | 0.0% | 451 | 0.0% | 0.00% | – |
Q4 2016 | $4,000 | +33.3% | 451 | +10.0% | 0.00% | – |
Q3 2016 | $3,000 | +50.0% | 410 | 0.0% | 0.00% | – |
Q2 2016 | $2,000 | -33.3% | 410 | 0.0% | 0.00% | – |
Q4 2015 | $3,000 | – | 410 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |